zerbor
4 June 2018Big Pharma

French court knocks out Gilead Truvada SPC

The Paris Court of First Instance has nullified a supplementary protection certificate (SPC) covering Gilead’s HIV/AIDS treatment Truvada.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Europe
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.

More on this story

Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Europe
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.

More on this story

Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Europe
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.